Dotmatics on KSNV: The Role of AI in Accelerating the Discovery of Life-Saving Medicines
In a KSNV interview, Phil Mounteney, VP of Science and Technology at Dotmatics, discusses how their AI-ready platform is revolutionizing drug discovery by enabling scientists to develop life-saving medicines more quickly and cost-effectively, potentially reducing drug development timelines from ten years to just a few and advancing personalized medicine.
Discover how artificial intelligence is transforming drug discovery in this compelling KSNV interview with Phil Mounteney, VP of Science and Technology at Dotmatics.
Learn how AI is helping scientists uncover life-saving medicines faster and more cost-effectively, potentially cutting drug development timelines from ten years to just a few. Phil shares fascinating insights into Dotmatics' innovative AI-ready platform and the future of personalized medicine.
Related
CBS News: How AI Is Accelerating Safer, More Personalized Drug Discovery
In a CBS News interview, Dotmatics VP Phil Mounteney explains how their internally developed AI models accelerate drug discovery by analyzing early-phase research data to shorten development cycles, reduce costs, and deliver safer, personalized therapies while maintaining data privacy.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
How AI is Transforming Drug Discovery
Dotmatics executives Kalim Saliba and Steve Tharp explain in an NBC News Boston feature how AI is revolutionizing drug discovery by enabling researchers to navigate complex data more efficiently, significantly reducing development time and costs, and accelerating the creation of safer, personalized medicines.
Techstrong TV: AI Leadership Insights for Scientific Research and Drug Discovery
In this Techstrong TV interview, Dotmatics CEO Thomas Swalla discusses how the company leverages AI to accelerate scientific research and drug discovery by streamlining workflows, enabling breakthroughs, and reducing costs in R&D.
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.